Spinal Cord Injury Program

About BioAxone Biosciences

BioAxone BioSciences is a private, clinical-stage biotech company pioneering treatments for severe neurological conditions, specifically spinal cord injury and cerebral cavernous malformation. The company's technology platform centers on modulating the Rho signaling pathway, a key regulator of neuronal repair and blood-brain barrier integrity. Led by a seasoned management team with strong academic and industry backgrounds, BioAxone is advancing neuroprotective and regenerative therapies in areas with no current pharmacological options. The company operates in high-need, niche markets with potential for significant impact and premium pricing.

About VersaPeutics

VersaPeutics is a private, pre-revenue biotech startup founded in 2016, targeting significant challenges in neuroscience. The company is in the early stages of building its scientific team and research programs, with a focus on translating recent breakthroughs in neuroscience into novel therapeutics. Its initial pipeline aims at Alzheimer's disease, spinal cord injury, and neuropathic pain, representing areas with substantial market need and limited treatment options. As a nascent company, its near-term goals are centered on securing investment, advancing its research platform, and progressing its lead candidates toward the clinic.

About Gel4Med

Gel4Med is a private, commercial-stage biotech company pioneering a bioinspired approach to tissue engineering through its patented Smart Materials Platform™. The company achieved a significant milestone in October 2023 with FDA 510(k) clearance for its lead products, G4Derm™ Plus and Suprello™, entering the large and growing advanced wound care market. With backing from competitive NIH grants and strategic collaborations, such as with the University of Miami for spinal cord injury, Gel4Med is positioned to expand its pipeline beyond wound care. The company's core strength lies in its engineered peptide-based matrices that aim to improve healing outcomes and address significant unmet clinical needs.

Therapeutic Areas

Other Spinal Cord Injury Drugs